A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Cetuximab; Cixutumumab
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly; ImClone Systems
- 31 Aug 2018 Biomarkers information updated
- 16 Aug 2010 Results published in the Journal of Clincal Oncology.
- 16 Aug 2010 Status changed from active, no longer recruiting to completed, based on an article published in the Journal of Clincal Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History